Table 1.

Isotype, binding and neutralization features of nine new RSV F-specific human mAbs or control mAbs

DonorMonoclonal antibodyIgG subclassLight chainNeutralization (IC50; ng/mL)Binding to F protein for indicated strain (EC50; ng/mL)
RSV A2RSV A2RSV A2 DS-Cav1RSV A2 SC-TMRSV 18537 B
24E71λ>19>11021
210F131κ>17669321
114C161κ>191109520
34B63λ>24>13024
19J51κ>30>15040
112I11λ>26>25033
114N41κ69578705757
413A81κ5582625264
23J201κ37784604850
Control mAbsMotavizumab1κ12330372835
101F1κ40250628045
D251κ21>8972>
  • EC50 values correspond to the concentration at which half-maximum signal was obtained in ELISA, based on optical density at 405 nm. Neutralization values were determined using a plaque-reduction assay, where the IC50 corresponds to the mAb concentration at which 50% plaque reduction was observed. > indicates no signal was detected below 100 μg/mL in neutralization assays and 20 μg/mL in ELISA binding assays; DS-Cav1 and SC-TM represent prefusion stabilized RSV F.